Press release
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference
Interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open-label study to be presented at a mini symposium An annual update of the
About this update from United Therapeutics Corporation
[{"type":"text","content":"\nInterim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open-label study to be presented at a mini symposium\n\nAn annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented at a poster session\n\n SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Francisco on May 16-21, 2025.\n\nAt ATS, United Therapeutics is sponsoring several events including the Respiratory Innovation Summit and the ATS Research Program Benefit Networking Event, and the company is hosting the Jenesis Innovative Research Awards™ Ceremony.\n\n“Our series of posters and presentations at ATS will showcase the most recent findings on several products across our core portfolio and ongoing development pipeline,” said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics. “We are pleased to present additional interim efficacy data from the ADVANCE EXTENSION open-label study evaluating ralinepag for pulmonary arterial hypertension, which has the potential, through once-daily dosing, to fundamentally change the positioning of prostacyclins in the treatment paradigm.”\n\nPosters, mini-symposia, and discussion sessions include:\n\nThematic poster session. Sunday, May 18, 11:30 a.m. to 1:15 p.m. PT: A48/P1624 – TETON Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis: Annual Update of Preliminary Baseline Data. Presented by Steven D. Nathan, M.D., Inova Fairfax Hospital.\n\nThematic poster session. Sunday, May 18, 11:30 a.m. to 1:15 p.m. PT: A48/P1623 – TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis: Preliminary Baseline Demographics. Presented by Steven D. Nathan, M.D., Inova Fairfax Hospital.\n\nPoster discussion session. Sunday, May 18, 2:15 p.m. to 4:15 p.m. PT: A104/908 – Expert Nurse Insights on the Future of Parenteral Prostacyclin Pumps for Pulmonary Arterial Hypertension. Presented by Lori Reed, N.P., Piedmont Healthcare.\n\nRapid abstract poster discu...